Free Trial
TSE:MDNA

Medicenna Therapeutics (MDNA) Stock Price, News & Analysis

C$2.34
-0.15 (-6.02%)
(As of 03:01 PM ET)
Today's Range
C$2.34
C$2.45
50-Day Range
C$1.37
C$2.82
52-Week Range
C$0.22
C$2.89
Volume
31,571 shs
Average Volume
131,117 shs
Market Capitalization
C$174.99 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
MDNA stock logo

About Medicenna Therapeutics Stock (TSE:MDNA)

Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. It develops MDNA55, an interleukin- 4 (IL-4) EC for the treatment of recurrent glioblastoma, as well as for brain tumors. The company also develops MDNA11, an enhanced version of IL-2 to activate and proliferate the immune cells needed to fight cancer; MDNA209, an IL-2 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host disease; MDNA413, a dual IL-4/IL-13 antagonist to treat cancer immunotherapies; and MDNA132, an IL-13 Superkine for solid tumors. In addition, it provides BiSKITs platform to develop designer Superkines by fusing them to other proteins, antibodies, cytokines, or other Superkines. The company is headquartered in Toronto, Canada.

MDNA Stock Price History

MDNA Stock News Headlines

See More Headlines
Receive MDNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Medicenna Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
5/23/2024
Next Earnings (Estimated)
6/25/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
16
Year Founded
N/A

Profitability

Net Income
C$-15,420,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Cash Flow
C$2.04 per share
Book Value
C$0.27 per share

Miscellaneous

Free Float
N/A
Market Cap
C$174.99 million
Optionable
Not Optionable
Beta
1.29
7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

  • Dr. Fahar Merchant Ph.D. (Age 67)
    Founder, Chairman, President & CEO
    Comp: $454.37k
  • Ms. Rosemina Merchant B.Sc. (Age 67)
    M.E.Sc, Founder & Chief Development Officer
    Comp: $364.46k
  • Mr. David Hyman CA (Age 51)
    CBV, Chief Financial Officer
  • Dr. Samuel R. Denmeade M.D.
    Scientific Advisor

MDNA Stock Analysis - Frequently Asked Questions

How have MDNA shares performed in 2024?

Medicenna Therapeutics' stock was trading at C$0.42 at the beginning of the year. Since then, MDNA stock has increased by 481.0% and is now trading at C$2.44.
View the best growth stocks for 2024 here
.

When is Medicenna Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, June 25th 2024.
View our MDNA earnings forecast
.

What other stocks do shareholders of Medicenna Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Medicenna Therapeutics investors own include OPKO Health (OPK), AbbVie (ABBV), Livongo Health (LVGO), Aptose Biosciences (APTO), Birchcliff Energy (BIR), CVS Health (CVS), Freehold Royalties (FRU), Fastly (FSLY) and Inovio Pharmaceuticals (INO).

How do I buy shares of Medicenna Therapeutics?

Shares of MDNA stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

This page (TSE:MDNA) was last updated on 5/23/2024 by MarketBeat.com Staff

From Our Partners